
Felicitex Therapeutics: Pioneering drug discovery for resistant cancers, enhancing treatment effectiveness.
Felicitex Therapeutics is a drug discovery company focused on developing novel treatments for dormant (quiescent) cancer cells. Their mission is to improve the effectiveness and long-term outcomes of treatments for highly resistant cancers, including hematopoietic, ovarian, pancreatic, colorectal, and lung cancers. The company's unique approach targets the "sleeping niche" of cancer cells, aiming to deprive them of their ability to enter a dormant state and make them more vulnerable to treatment.
Felicitex Therapeutics has made significant progress in their research, with three clinical drug candidates ready for IND enabling studies. Their innovative strategy addresses critical challenges in oncology, including cancer resistance, metastasis, and relapse. By targeting the mechanism of cancer survival and acquired resistance, Felicitex is positioned at the forefront of developing potentially groundbreaking therapies for some of the most challenging forms of cancer.
Felicitex Therapeutics' most recent funding round was for $200k (USD) in June 2015.
As of Jun 24, 2015, Felicitex Therapeutics has disclosed funding of $200k (USD).

HiberCell
hibercell.com

Stelexis Therapeutics
stelexis.com

TAXIS Pharmaceuticals
taxispharma.com

Resilience Therapeutics

Dialectic Therapeutics
dtsciences.com

Etira
etira.life

Facile Therapeutics

Senex Biotechnology
senexbio.com

XTuit Pharmaceuticals
xtuit.com

Telo Therapeutics

Canget BioTekpharma
canget-biotek.com

Nexcida Therapeutics

Vivace Therapeutics

Thetis Pharmaceuticals
thetispharma.com

Fog Pharmaceuticals
fogpharma.com

Vivacitas Oncology
vivaoncology.com

Tetherex Pharmaceuticals

TumorGen
tumorgen.net

Elicio Therapeutics
elicio.com

Palm Therapeutics